Wockhardt Share Price Surges 19% After USFDA Nod for Novel Antibiotic Zaynich

Wockhardt share price (NSE: WOCKPHARMA) surged sharply on June 1 after the company received approval from the US Food and Drug Administration (USFDA) for Zaynich, a new antibiotic developed to treat complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), in adults.

The stock climbed as much as 19% during intraday trade and touched a record high of ₹2,420. Over the past month, Wockhardt shares have gained nearly 75%, significantly outperforming the broader market.

What Is Driving Wockhardt Share PriceRally?

The biggest trigger for the stock is the USFDA approval of Zaynich, a combination of cefepime and zidebactam.

The drug is designed to treat serious infections caused by antibiotic-resistant bacteria, an area where demand is growing globally due to rising antimicrobial resistance.

According to the company, more than 2.8 million antimicrobial-resistant infections occur every year in the United States, resulting in over 35,000 deaths. Complicated urinary tract infections account for more than 600,000 hospitalisations annually in the country.

A Milestone for Indian Pharma

Zaynich is considered a significant achievement because it is the first new chemical entity (NCE) fully discovered, developed and commercialised by an Indian pharmaceutical company to receive USFDA approval.

The approval highlights Wockhardt's long-term investment in developing innovative anti-infective medicines rather than relying solely on generic drugs.

Strong Antibiotic Pipeline

Wockhardt currently has 6 antibiotics under development and commercialisation.

• 3 drugs target Gram-negative bacterial infections.
• 3 drugs target Gram-positive bacterial infections.
• All 6 have received Qualified Infectious Disease Product (QIDP) designation from the USFDA.

The company also has 3 anti-infective products under priority review, with Zaynich becoming the first among them to secure approval.

Wockhardt Financial Performance

Wockhardt has taken several steps to improve profitability, including:

• Increasing focus on higher-margin businesses.
• Implementing cost-control measures.
• Exiting its loss-making US generics business.

As a result, the company reported revenue growth of 12.9% in FY26. Operating profit margin improved to 19.2% in FY26 from 13.1% in FY25.

Growth was driven by expanding biosimilar sales in emerging markets and steady performance in India and Europe.

Read More: Reliance Retail's Luxury Arm Revenue Rises 45% to ₹3,494 Crore, Net Loss Narrows 51% in FY26!

Wockhardt Share Price Performance

The positive developments have led to strong investor interest in the stock. On June 1, Wockhardt touched an all-time high of ₹2,420 and witnessed heavy trading volumes across exchanges.

At around 2:49 PM IST, the stock was trading at ₹2,189.10, up 7.76% for the day. It moved between an intraday low of ₹2,126.40 and a high of ₹2,422.30, which also marked its 52-week high. The stock's 52-week low stands at ₹1,086.70.

Conclusion

Wockhardt's recent rally has been driven primarily by the landmark USFDA approval of Zaynich, a novel antibiotic targeting drug-resistant infections. Combined with a strong pipeline, improving financial performance, and a recent credit rating upgrade, the approval has strengthened investor confidence in the company's long-term growth prospects. The commercial success of Zaynich will now be a key factor to watch in the coming years.

Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.